CureVac NV (CVAC)vsBeiGene, Ltd. (ONC)
CVAC
CureVac NV
$4.66
0.00%
HEALTHCARE · Cap: $1.05B
ONC
BeiGene, Ltd.
$327.21
-0.98%
HEALTHCARE · Cap: $34.29B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 8013% more annual revenue ($5.74B vs $70.74M). CVAC leads profitability with a 182.1% profit margin vs 8.9%. CVAC trades at a lower P/E of 7.0x. CVAC earns a higher WallStSmart Score of 56/100 (C).
CVAC
Buy56
out of 100
Grade: C
ONC
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+63.5%
Fair Value
$12.77
Current Price
$4.66
$8.11 discount
Margin of Safety
+81.1%
Fair Value
$1857.02
Current Price
$327.21
$1529.81 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 182 of every $100 in revenue as profit
Strong operational efficiency at 573.0%
Safe zone — low bankruptcy risk
Every $100 of equity generates 22 in profit
Revenue surging 35.5% year-over-year
Earnings expanding 16971.0% YoY
Conservative balance sheet, low leverage
Areas to Watch
Smaller company, higher risk/reward
Revenue declined 89.0%
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : CVAC
The strongest argument for CVAC centers on P/E Ratio, Price/Book, Profit Margin. Profitability is solid with margins at 182.1% and operating margin at 573.0%.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 35.5% demonstrates continued momentum.
Bear Case : CVAC
The primary concerns for CVAC are Market Cap, Revenue Growth.
Bear Case : ONC
The primary concerns for ONC are P/E Ratio, Altman Z-Score. A P/E of 74.6x leaves little room for execution misses.
Key Dynamics to Monitor
CVAC profiles as a declining stock while ONC is a hypergrowth play — different risk/reward profiles.
CVAC carries more volatility with a beta of 1.84 — expect wider price swings.
ONC is growing revenue faster at 35.5% — sustainability is the question.
ONC generates stronger free cash flow (161M), providing more financial flexibility.
Bottom Line
CVAC scores higher overall (56/100 vs 54/100), backed by strong 182.1% margins. ONC offers better value entry with a 81.1% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CureVac NV
HEALTHCARE · BIOTECHNOLOGY · USA
CureVac NV, a clinical-stage biopharmaceutical company, is focused on developing various transformative drugs based on messenger ribonucleic acid (mRNA). The company is headquartered in Tbingen, Germany.
Visit Website →BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?